+++
date = ""
draft = true
layout = "blocks"
title = "Upadacitinib EMA approval"
[[page_sections]]
backgroundColor = "#36E4DA"
block = "text-only-hero-banner"
heading = "January 25th 2021: European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis"
template = "text-only-hero-banner"
textColor = ""
[[page_sections]]
alignment = "left"
block = "one-column-1"
content = "I hope that you are all having a lovely weekend (or as much as it can be at the moment!). Some exciting news this week – a new drug called Upadacitinib has been approved by the European Medicines Agency (EMA), for use in Ankylosing Spondylitis (AS, radiographic axial spondyloarthritis – where changes can be seen on X-ray).<br><br>In light of this exciting news, we thought that it would be interesting to provide some more information about this novel drug below. We hope that you find it useful!<br><br>Enjoy the rest of the weekend.<br><br>Best wishes,<br>The Project Nightingale Team"
has_padding = true
headerColor = "#9013FE"
headline = "Hi everyone!"
template = "1-column-text"
textAlignment = "left"
textColor = ""

+++
